These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15867606)

  • 1. Basic pharmacological interactions and how they may impact on one another.
    Benet L
    J Acquir Immune Defic Syndr; 2005 Mar; 38 Suppl 1():S22-3. PubMed ID: 15867606
    [No Abstract]   [Full Text] [Related]  

  • 2. P glycoprotein in human immunodeficiency virus type 1 infection and therapy.
    Sankatsing SU; Beijnen JH; Schinkel AH; Lange JM; Prins JM
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1073-81. PubMed ID: 15047504
    [No Abstract]   [Full Text] [Related]  

  • 3. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.
    Huisman MT; Smit JW; Schinkel AH
    AIDS; 2000 Feb; 14(3):237-42. PubMed ID: 10716499
    [No Abstract]   [Full Text] [Related]  

  • 4. Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.
    Pal D; Kwatra D; Minocha M; Paturi DK; Budda B; Mitra AK
    Life Sci; 2011 May; 88(21-22):959-71. PubMed ID: 20932495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of human CYP3A and P-glycoprotein on the absorption of drugs.
    van de Waterbeemd H
    Eur J Pharm Sci; 2000 Nov; 12(1):1. PubMed ID: 11121728
    [No Abstract]   [Full Text] [Related]  

  • 6. Natural products and adverse drug interactions.
    Bailey DG; Dresser GK
    CMAJ; 2004 May; 170(10):1531-2. PubMed ID: 15136542
    [No Abstract]   [Full Text] [Related]  

  • 7. P-Glycoprotein in clinical cardiology.
    Rodriguez I; Abernethy DR; Woosley RL
    Circulation; 1999 Feb; 99(4):472-4. PubMed ID: 9927391
    [No Abstract]   [Full Text] [Related]  

  • 8. Structure-activity relationships of cyclotetrapeptides: interaction of tentoxin derivatives with three membrane proteins.
    Loiseau N; Delaforge M; Minoletti C; André F; Garrigues A; Orlowski S; Gomis JM
    Adv Exp Med Biol; 2001; 500():343-6. PubMed ID: 11764966
    [No Abstract]   [Full Text] [Related]  

  • 9. Carrier-mediated transport of macrolide antimicrobial agents across Caco-2 cell monolayers.
    Saito H; Fukasawa Y; Otsubo Y; Yamada K; Sezaki H; Yamashita S
    Pharm Res; 2000 Jun; 17(6):761-5. PubMed ID: 10955854
    [No Abstract]   [Full Text] [Related]  

  • 10. Polarized cell cultures for integrated studies of drug metabolism and transport.
    Brimer-Cline C; Schuetz EG
    Methods Enzymol; 2002; 357():321-9. PubMed ID: 12424922
    [No Abstract]   [Full Text] [Related]  

  • 11. PharmGKB summary: Efavirenz pathway, pharmacokinetics.
    McDonagh EM; Lau JL; Alvarellos ML; Altman RB; Klein TE
    Pharmacogenet Genomics; 2015 Jul; 25(7):363-76. PubMed ID: 25966836
    [No Abstract]   [Full Text] [Related]  

  • 12. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.
    Wacher VJ; Wu CY; Benet LZ
    Mol Carcinog; 1995 Jul; 13(3):129-34. PubMed ID: 7619215
    [No Abstract]   [Full Text] [Related]  

  • 13. Gender: a possible determinant in dosing of dermatologic drugs--an overview.
    Modjtahedi BS; Modjtahedi SP; Maibach HI
    Cutan Ocul Toxicol; 2006; 25(3):195-210. PubMed ID: 16980245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities.
    Kirby B; Kharasch ED; Thummel KT; Narang VS; Hoffer CJ; Unadkat JD
    J Clin Pharmacol; 2006 Nov; 46(11):1313-9. PubMed ID: 17050796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and metabolism in early drug discovery.
    Smith DA; van de Waterbeemd H
    Curr Opin Chem Biol; 1999 Aug; 3(4):373-8. PubMed ID: 10419843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.
    Yu DK
    J Clin Pharmacol; 1999 Dec; 39(12):1203-11. PubMed ID: 10586385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Mathematical simulation to explain the coordinated functions of efflux and metabolism limiting the transport of anti-HIV agents across Caco-2 cells.
    Patel J; Hussain A; Pal D; Mitra AK
    Am J Ther; 2004; 11(2):114-23. PubMed ID: 14999363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Table: Inhibitors and inducers of CYP enzymes and P-glycoprotein.
    Med Lett Drugs Ther; 2020 Sep; 62(1607):e152-e153. PubMed ID: 32960871
    [No Abstract]   [Full Text] [Related]  

  • 20. Drugs as CYP3A probes, inducers, and inhibitors.
    Liu YT; Hao HP; Liu CX; Wang GJ; Xie HG
    Drug Metab Rev; 2007; 39(4):699-721. PubMed ID: 18058330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.